Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Oncology Institute (TOI) Shares Repurchased (2023)

Oncology Institute's Shares Repurchased history spans 1 years, with the latest figure at $125000.0 for Q3 2023.

For Q3 2023, Shares Repurchased changed N/A year-over-year to $125000.0; the TTM value through Dec 2024 reached $125000.0, changed 0.0%, while the annual FY2023 figure was $1.0 million, 88.68% down from the prior year.
Shares Repurchased reached $125000.0 in Q3 2023 per TOI's latest filing.
In the past five years, Shares Repurchased ranged from a high of $125000.0 in Q3 2023 to a low of $125000.0 in Q3 2023.